Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

The treatment of people with type 2 diabetes (T2D) has changed substantially in the last decade. Three novel glucose-lowering drug classes —incretin-based therapies and sodium‒glucose cotransporter-2 inhibitors—entered clinical guidelines with evidence from now 18 landmark trials.1 Glucose-lowering drugs were historically approved on glycated hemoglobin (HbA1C)-lowering and safety in several hundred T2D participants over only sev eral months; since 2008, regulatory agencies have required randomized, controlled trials (RCTs) focusing on cardiovascular (CV) safety (cardiovascular outcome trials, CVOTs) involving several thousand participants and several years of follow-up with major adverse cardiovascular event as the primary outcome.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Controversies in Nephrology Source Type: research